Synergistic suppression of prostatic cancer cells by coexpression of both Murine Double Minute 2 small interfering RNA and wild-type p53 gene in vitro and in vivo

Journal of Pharmacology and Experimental Therapeutics

Volumn 338, Issue 1, 2011, Pages 173-183

  Ji, Kun ^a,b   Wang, Bo ^a,c,d   Shao, Yue Ting ^a   Zhang, Ling ^a   Liu, Ya Nan ^a   Shao, Chen ^a   Li, Xiao Jie ^a   Li, Xin ^a   Hu, Jia Di ^e   Zhao, Xue Jian ^a   Xu, De Qi ^f   Li, Yang ^a   Cai, Lu ^d  

^a JILIN UNIVERSITY   (China)

^b SHENYANG MEDICAL COLLEGE   (China)

^c Inner Mongolia Forestry General Hospital   (China)

^d University of Louisville School of Medicine   (United States)

^e UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

^f CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; MUTANT PROTEIN; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; SALMONELLOSIS VACCINE; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL GROWTH; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MURINE DOUBLE MINUTE 2 GENE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RECOMBINANT PLASMID; REGULATOR GENE; SALMONELLA ENTERICA; SALMONELLA TYPHI; SEROTYPE; TUMOR SUPPRESSOR GENE; UPREGULATION; WILD TYPE;

ANIMALS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; MALE; MICE; MICE, NUDE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MDM2; RANDOM ALLOCATION; RNA, SMALL INTERFERING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79959492523     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.180364     Document Type: Article

References (40)

1. References Bernal F, Wade M, Godes M, Davis TN, Whitehead DG, Kung AL, Wahl GM, and Walensky LD (2010) A stapled p53 helix overcomes HDMX-mediated suppression of p53. Cancer Cell 18:411-422.
2. Chène P (2003) Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat Rev Cancer 3:102-109.
3. Clairmont C, Lee KC, Pike J, Ittensohn M, Low KB, Pawelek J, Bermudes D, Brecher SM, Margitich D, Turnier J, et al. (2000) Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium. J Infect Dis 181:1996-2002. (Pubitemid 30416163)
4. Cryz SJ Jr, Vanprapar N, Thisyakorn U, Olanratmanee T, Losonsky G, Levine MM, and Chearskul S (1993) Safety and immunogenicity of Salmonella typhi Ty21a vaccine in young Thai children. Infect Immun 61:1149-1151. (Pubitemid 23059683)
5. Deng WG, Kawashima H, Wu G, Jayachandran G, Xu K, Minna JD, Roth JA, and Ji L (2007) Synergistic tumor suppression by coexpression of FUS1 and p53 is associated with down-regulation of murine double minute-2 and activation of the apoptotic protease-activating factor 1-dependent apoptotic pathway in human non-small cell lung cancer cells. Cancer Res 67:709-717. (Pubitemid 46192211)
6. Derweesh IH, Kupelian PA, Zippe C, Levin HS, Brainard J, Magi-Galluzzi C, Myles J, Reuther AM, and Klein EA (2004) Continuing trends in pathological stage migration in radical prostatectomy specimens. Urol Oncol 22:300-306. (Pubitemid 38993307)
7. Freytag SO, Stricker H, Peabody J, Pegg J, Paielli D, Movsas B, Barton KN, Brown SL, Lu M, and Kim JH (2007) Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer. Mol Ther 15:636-642.
8. Gottifredi V and Prives C (2001) Molecular biology. Getting p53 out of the nucleus. Science 292:1851-1852.
9. Hainaut P and Hollstein M (2000) p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 77:81-137. (Pubitemid 29439303)
10. Hsieh JK, Fredersdorf S, Kouzarides T, Martin K, and Lu X (1997) E2F1-induced apoptosis requires DNA binding but not transactivation and is inhibited by the retinoblastoma protein through direct interaction. Genes Dev 11:1840-1852. (Pubitemid 27315213)
11. Isaacs WB, Carter BS, and Ewing CM (1991) Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 51:4716-4720.
12. Kamangar F, Dores GM, and Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24:2137-2150. (Pubitemid 46655601)
13. Kimura H, Zhang L, Zhao M, Hayashi K, Tsuchiya H, Tomita K, Bouvet M, Wessels J, and Hoffman RM (2010) Targeted therapy of spinal cord glioma with a genetically modified Salmonella typhimurium. Cell Prolif 43:41-48.
14. Kowalik TF, DeGregori J, Leone G, Jakoi L, and Nevins JR (1998) E2F1-specific induction of apoptosis and p53 accumulation, which is blocked by Mdm2. Cell Growth Differ 9:113-118. (Pubitemid 128472551)
15. Lee CH, Wu CL, and Shiau AL (2004) Endostatin gene therapy delivered by Salmonella choleraesuis in murine tumor models. J Gene Med 6:1382-1393.
16. Martin K, Trouche D, Hagemeier C, Sørensen TS, La Thangue NB, and Kouzarides T (1995) Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 375:691-694.
17. Momand J, Zambetti GP, Olson DC, George D, and Levine AJ (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237-1245.
18. Mu Z, Hachem P, Agrawal S, and Pollack A (2004a) Antisense MDM2 oligonucleotides restore the apoptotic response of prostate cancer cells to androgen deprivation. Prostate 60:187-196. (Pubitemid 38971830)
19. Mu Z, Hachem P, Agrawal S, and Pollack A (2004b) Antisense MDM2 sensitizes prostate cancer cells to androgen deprivation, radiation, and the combination. Int J Radiat Oncol Biol Phys 58:336-343. (Pubitemid 38142457)
20. Mu Z, Hachem P, Hensley H, Stoyanova R, Kwon HW, Hanlon AL, Agrawal S, and Pollack A (2008) Antisense MDM2 enhances the response of androgen insensitive human prostate cancer cells to androgen deprivation in vitro and in vivo. Prostate 68:599-609. (Pubitemid 351614638)
21. Mu Z, Hachem P, and Pollack A (2005) Antisense Bcl-2 sensitizes prostate cancer cells to radiation. Prostate 65:331-340. (Pubitemid 41759965)
22. Nishizaki M, Sasaki J, Fang B, Atkinson EN, Minna JD, Roth JA, and Ji L (2004) Synergistic tumor suppression by coexpression of FHIT and p53 coincides with FHIT-mediated MDM2 inactivation and p53 stabilization in human non-small cell lung cancer cells. Cancer Res 64:5745-5752. (Pubitemid 39095573)
23. Patton JT, Mayo LD, Singhi AD, Gudkov AV, Stark GR, and Jackson MW (2006) Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Res 66:3169-3176.
24. Pawelek JM, Low KB, and Bermudes D (1997) Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res 57:4537-4544. (Pubitemid 27441058)
25. Shao Y, Liu Y, Shao C, Hu J, Li X, Li F, Zhang L, Zhao D, Sun L, Zhao X, et al. (2010) Enhanced tumor suppression in vitro and in vivo by co-expression of survivinspecific siRNA and wild-type p53 protein. Cancer Gene Ther 17:844-854.
26. Stoeltzing O, McCarty MF, Wey JS, Fan F, Liu W, Belcheva A, Bucana CD, Semenza GL, and Ellis LM (2004) Role of hypoxia-inducible factor 1alpha in gastric cancer cell growth, angiogenesis, and vessel maturation. J Natl Cancer Inst 96:946-956. (Pubitemid 38868141)
27. Stoyanova R, Hachem P, Hensley H, Khor LY, Mu Z, Hammond ME, Agrawal S, and Pollack A (2007) Antisense-MDM2 sensitizes LNCaP prostate cancer cells to androgen deprivation, radiation, and the combination in vivo. Int J Radiat Oncol Biol Phys 68:1151-1160. (Pubitemid 47053953)
28. Tao W and Levine AJ (1999) Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. Proc Natl Acad Sci USA 96:3077-3080. (Pubitemid 29148846)
29. Thamm DH, Kurzman ID, King I, Li Z, Sznol M, Dubielzig RR, Vail DM, and MacEwen EG (2005) Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluation. Clin Cancer Res 11:4827-4834. (Pubitemid 41557202)
30. Vousden KH and Lane DP (2007) p53 in health and disease. Nat Rev Mol Cell Biol 8:275-283. (Pubitemid 46474662)
31. Wade M and Wahl GM (2009) Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry? Mol Cancer Res 7:1-11.
32. Wade M, Wong ET, Tang M, Stommel JM, and Wahl GM (2006) Hdmx modulates the outcome of p53 activation in human tumor cells. J Biol Chem 281:33036-33044. (Pubitemid 46036686)
33. Wiman KG (2006) Strategies for therapeutic targeting of the p53 pathway in cancer. Cell Death Differ 13:921-926.
34. Xiao ZX, Chen J, Levine AJ, Modjtahedi N, Xing J, Sellers WR, and Livingston DM (1995) Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375:694-698.
35. Yamakuchi M, Lotterman CD, Bao C, Hruban RH, Karim B, Mendell JT, Huso D, and Lowenstein CJ (2010) P53-induced microRNA-107 inhibits HIF-1 and tumor angiogenesis. Proc Natl Acad Sci USA 107:6334-6339.
36. Zhang L, Gao L, Li Y, Lin G, Shao Y, Ji K, Yu H, Hu J, Kalvakolanu DV, Kopecko DJ, et al. (2008) Effects of plasmid-based Stat3-specific short hairpin RNA and GRIM-19 on PC-3M tumor cell growth. Clin Cancer Res 14:559-568. (Pubitemid 351226126)
37. Zhang L, Gao L, Zhao L, Guo B, Ji K, Tian Y, Wang J, Yu H, Hu J, Kalvakolanu DV, et al. (2007) Intratumoral delivery and suppression of prostate tumor growth by attenuated Salmonella enterica serovar typhimurium carrying plasmid-based small interfering RNAs. Cancer Res 67:5859-5864. (Pubitemid 46985020)
38. Zhang Y, Shi Y, Li X, Du W, Luo G, Gou Y, Wang X, Guo X, Liu J, Ding J, et al. (2010) Inhibition of the p53-MDM2 interaction by adenovirus delivery of ribosomal protein L23 stabilizes p53 and induces cell cycle arrest and apoptosis in gastric cancer. J Gene Med 12:147-156.
39. Zhao M, Yang M, Li XM, Jiang P, Baranov E, Li S, Xu M, Penman S, and Hoffman RM (2005) Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc Natl Acad Sci USA 102:755-760. (Pubitemid 40282738)
40. Zheng QH, Ma LW, Zhu WG, Zhang ZY, and Tong TJ (2006) p21Waf1/Cip1 plays a critical role in modulating senescence through changes of DNA methylation. J Cell Biochem 98:1230-1248. (Pubitemid 44128362)